Nasdaq:US$36.56 (-0.93) | HKEX:HK$57.55 (-1.15) | AIM:£5.26 (-0.12)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer